Elevance Health, Inc.
No SEC Form 4 filings for $ELV in the last 30 days.
See all $ELV insider activity →Elevance Health's EVP & Chief Legal Officer, Erin M. Wessling, disposed of 349 shares to cover tax liability on vesting restricted stock. The transactions occurred on September 2 and 3, 2026, at prices of $405.84 and $414.78 per share, respectively. No Rule 10b5-1 trading plan was reported.
Elevance Health (ELV) reported that EVP & Chief HR Officer Ryan R. Craig had 144 shares withheld for taxes on Sept 2, 2026, due to restricted stock vesting. The shares were valued at $405.84 each, leaving Craig with 6,530 shares. No Rule 10b5-1 trading plan was involved.
Elevra Lithium (ASX:ELV) reported a full-year earnings turnaround with sales of US$201.68 million and net income of US$43.07 million. The company secured a 7-year spodumene supply deal with Mangrove Lithium, improving revenue visibility and cost profile. Despite the positive results, the stock fell 5.2%, possibly due to sensitivity to lithium prices.
Over the past 7 days, alphai's AI scored 4 news stories mentioning ELV (Elevance Health, Inc.). Coverage has skewed bullish: 1 bullish, 3 neutral, and 0 bearish.
Recent ELV coverage spans earnings, financial news and regulation.
Small insider tax‑withholding sale of ~144k USD worth of shares.
Small insider tax‑withholding transaction (~$58K) with no 10b5‑1 plan; unlikely to affect share supply or price.
The earnings turnaround plus a long-term offtake should improve near-term revenue visibility, but the stock is down on lingering lithium-price sensitivity.
Potential rejection could limit revenue growth from rate hikes.
Elevance Health is highlighted for comparative analysis with peers.
alphai scores every news story that mentions ELV with an AI model for sentiment and relevance, and aggregates insider trades from Elevance Health, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Elevance Health's EVP & Chief Legal Officer, Erin M. Wessling, disposed of 349 shares to cover tax liability on vesting restricted stock. The transactions occurred on September 2 and 3, 2026, at prices of $405.84 and $414.78 per share, respectively. No Rule 10b5-1 trading plan was reported.
1 min readElevance Health (ELV) reported that EVP & Chief HR Officer Ryan R. Craig had 144 shares withheld for taxes on Sept 2, 2026, due to restricted stock vesting. The shares were valued at $405.84 each, leaving Craig with 6,530 shares. No Rule 10b5-1 trading plan was involved.
1 min readElevra Lithium (ASX:ELV) reported a full-year earnings turnaround with sales of US$201.68 million and net income of US$43.07 million. The company secured a 7-year spodumene supply deal with Mangrove Lithium, improving revenue visibility and cost profile. Despite the positive results, the stock fell 5.2%, possibly due to sensitivity to lithium prices.
6 min readConnecticut Attorney General William Tong urged the state's Insurance Department to reject double-digit rate hike requests from Anthem, ConnectiCare, and UnitedHealthcare for individual and small group health plans. The insurers seek increases ranging from 12.8% to 22.7% for 220,000 people. Tong cited concerns over rising costs and poor customer service, particularly from ConnectiCare. The Insurance Department will hold a public session on August 26 to review the requests.
2 min readCVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. UnitedHealth (UNH) reported $112B revenue, flat YoY, also beating estimates. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, missing guidance. Molina Healthcare (MOH) reported $10.87B revenue, down 4.8% YoY, missing guidance. All stocks have declined since earnings.
3 min readElevance Health (ELV) reported stronger Q2 2026 results, raising full-year EPS guidance to at least $20.10. The company highlighted AI-driven efficiency gains and appointed a new leader for its behavioral health services. Analysts note potential margin improvements but caution about elevated medical costs and policy risks. Revenue and earnings projections for 2029 are $209.8 billion and $7.3 billion, respectively.
3 min readElevance Health (ELV) has a market cap of $86.9B. Its stock rose 27.6% over 52 weeks, outperforming the S&P 500. Q2 2026 revenue was $49.8B, adjusted EPS $7.45. The company raised EPS and cash flow guidance. Analysts expect a 10.3% YOY EPS decline for 2026, but ELV has beaten estimates for four straight quarters. The consensus rating is 'Moderate Buy' with a mean price target of $445.71.
2 min readElevance Health (ELV), a large U.S. health insurer, reported $198.7B in revenue, 7.2% annual EPS growth, and 14.7x forward P/E. The company's market position and returns on capital are highlighted as strengths. A full research report is available for further analysis.
1 min readA Virginia federal court approved a $14.75 million settlement for Elevance Health to resolve lawsuits by nurses who claimed misclassification. The deal ends five related cases against the insurer.
1 min readMcKesson (MCK) fell 9.1% post-earnings despite a solid quarter. AdaptHealth (AHCO) missed revenue and EBITDA estimates, down 46.2%. Elevance Health (ELV) beat revenue and EPS estimates but lost customers, down 7.4%. Quest (DGX) topped expectations, up 12.6%.
3 min read
%252FElevance%252520Health%252520world%252520headquarters%252520By%252520jetcityimage.jpeg&w=3840&q=75)
